Image

Global Treatment-Resistant Depression Market - Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Upcoming Report
  • Apr 2020
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Apr 2020
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Treatment-Resistant Depression Market, By Drug Class (Selective Serotonin Reuptake Inhibitors (SSRIS), Monoamine Oxidase Inhibitors, Tricyclic Antidepressant, Psychedelics, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2027

Market Analysis and Insights: Global Treatment-Resistant Depression Market

Treatment-resistant depression market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market.

The growth of treatment-resistant depression market enhanced by the growing cases of mental illness and rise in research and development activities conducted by many pharmaceuticals’ companies. In addition, advances in the treatment rate and adoption of sedentary life-style are some of the impacting factors for the demand of treatment-resistant depression drugs. Nevertheless, product recalls coupled with shortage of drugs are the factors that hinder the growth of this market.

Morbidity and mortality worldwide resulting from psychiatric disorder predominantly by depression. Common treatments for depression are effective for most diseased burden in the world. patients however, some patients do not respond any of the antidepressant treatment. Patient suffering from depression and who have failed at least two trials of antidepressants medication that includes SSRI and SSNRI are generally comprised the population called treatment-resistant depression. 

Treatment-resistant depression market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Treatment-Resistant Depression Market Scope and Market Size

Treatment-resistant depression market is segmented on the basis of drug class, route of administration, end-users and distribution channel.

  • On the basis of drug class, the global treatment-resistant depression market is segmented into selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors, tricyclic antidepressant, psychedelics and others.
  • Based on route of administration, the treatment-resistant depression market is segmented into oral, parenteral and others.
  • On the basis of end-users, the treatment-resistant depression market is segmented into hospitals, homecare, specialty clinics and others.
  • On the basis of distribution channel, the treatment-resistant depression market has been bifurcated into hospital pharmacy, online pharmacy and retail pharmacy.

Global Treatment-Resistant Depression Market Country Level Analysis

Global treatment-resistant depression market is analyzed and market size information is provided by country, drug class, route of administration, end-users and distribution channel as referenced above.

The countries covered in the global treatment-resistant depression market  report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, in the Asia-Pacific, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

North America has been witnessing a positive growth for treatment-resistant depression market throughout the forecasted period owing to the global leaders in research and development activities, established framework of approval process and increase in number of FDA approval drugs. Europe is considered a second largest growing regional segment due to the high cases of mental illness. Asia-Pacific leads the market due to the developing healthcare facilities, large number of generic manufacturer and rise in government initiatives and specialist communities.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Global treatment-resistant depression market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Treatment-Resistant Depression Market Share Analysis

Global treatment-resistant depression market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to treatment-resistant depression market.

The major players covered in the global treatment-resistant depression market are Johnson & Johnson Services, Inc, Mallinckrodt plc, Sun Pharmaceutical Industries Ltd., Novartis AG, Endo Pharmaceuticals plc, Zydus Cadila, Mylan N.V., Mayne Pharma Group Limited, Teva Pharmaceutical Industries Ltd, Amneal Pharmaceutical Inc, Avet Pharmaceuticals Inc., Lannett, Aurobindo Pharma, Wockhardt, Currax Pharmaceuticals LLC and others.


SKU-
Why Choose Us


Frequently Asked Questions